インスリン新薬とドラッグデリバリー新技術の世界市場：注射器とバイアルを中心に

Report Highlights

The global market for emerging insulin drug delivery devices is expected to grow from $55.8 billion in 2023 and projected to reach $88.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.8% from 2023 through 2028.

インスリン新薬とドラッグデリバリー新技術の世界市場は、2023 年の 558 億ドルから成長し、2023 年から 2028 年までの年間平均成長率 (CAGR) 9.8% で、2028 年末までに 889 億ドルに達すると予測されています。

Summary:

BCC Research’s analysis revealed that the fastest-growing market segment is smart pens, which is expected to grow at a predicted CAGR of REDACTED% during the forecast period. The insulin syringes and vials segment is expected to have the slowest growth rate, a CAGR of REDACTED%.

Reasons for Doing the Study:

The increase in prevalence of diabetes mellitus, including type 2 diabetes worldwide, the most prevalent form, has reached epidemic levels. Concurrently, instances of type 1 diabetes mellitus are on the rise, albeit to a lesser extent. These escalating trends raise significant alarm, impacting not only those affected but also governments and healthcare providers, as the economic ramifications of diabetes are substantial. They involve the direct burden of managing the disease and its common and often catastrophic complications, including cardiovascular disease, peripheral neuropathy and blindness.

Ensuring timely diagnosis of diabetes and delivering efficient treatment are priorities for governments and healthcare organizations. As the prevalence of the diabetes continues to rise and diagnostic methods advance, the existing market for insulin drug and delivery technologies is expected to expand significantly. Consequently, diabetes holds substantial commercial importance for both the manufacturers of treatment drugs and the producers of monitoring devices.

For companies in this sector to strengthen their market position, they require precise and current evaluations of the present magnitude of the diabetes epidemic, as well as its probable trajectory over the upcoming five years, and the potential impact of insulin drug and delivery devices and technical developments now in the pipeline.

The market for insulin drug and delivery technologies will continue to grow significantly in many areas, notably regulatory compliance.

Report Scope:

This report discusses the implications of the growing diabetes epidemic on the global and regional markets for emerging insulin drug and delivery technologies. It discusses companies in the relevant pharmaceutical and medical industries and provides profiles of the leading players as well as an update on M&A activity. The report’s patent analysis focuses on developments in Japan, Europe and the U.S. Five-year global sales forecasts are provided for the major categories of insulin drug and delivery technologies and devices categories.

This report segments the global market into four regions –

• North America.
• Europe.
• Asia-Pacific.
• Rest of the World (RoW).

Report Synopsis

Report Includes:

• 57 data tables and 83 additional tables
• An overview and industry analysis of the global markets for emerging insulin drug and delivery technologies, with an emphasis on plastic insulin syringes and vials
• Analyses of the global market trends, with historical market revenue data (sales figures) for 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Estimate of the actual market size and revenue growth forecast, and a corresponding market share analysis by product type, application and region
• A look at the emerging technologies that have potential in the diabetes market, with improved glucose control, along with improved delivery methods
• Examination of the current state of the insulin drug and delivery industry structure, focusing on technological updates and issues surrounding insulin pens and insulin syringes, ongoing research activities, and regulatory and pricing scenarios
• Discussion of market dynamics, clinical trial applications, regulations, and penetration of technologies in the pharmaceutical and biotechnology markets
• Discussion of the ESG developments and how they impact corporate performance, ratings and matrices and consumer attitude, as well as the ESG practices of leading pharma and biotech companies
• Review of the key patent grants/publications for insulin as a drug, along with its delivery methods
• Analysis of the competitive landscape based on recent developments and segmental revenues of leading companies
• Profiles of the leading market players

Table of Contents
Chapter 1 Introduction
Overview
Study Goals and Objectives
Reasons for Doing the Study
What’s New in this Report?
Scope of Report
Information Sources
Methodology
Secondary Research
Geographic Breakdown
Segmentation Breakdown
Chapter 2 Summary and Highlights
Market Outlook
Market Summary
Developments and Trends
Chapter 3 Market Overview
Introduction
What is Diabetes?
Types of Diabetes
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes Mellitus or Hyperglycemia in Pregnancy
Impaired Glucose Tolerance and Impaired Fasting Glucose
Epidemiology of Diabetes
Gender Distribution
Regional Disparities
Market Dynamics Snapshot
Factors Affecting the Market
Market Drivers
Market Restraints
Chapter 4 Global Market for Emerging Insulin Drug and Delivery Technologies, by Type
Overview
Technological Advances in Insulin Syringes
Insulin Delivery Pen Devices
Disposable Insulin Pens
Reusable Insulin Pens
Technological Advances in Insulin Drug and Delivery Pen Devices
External Insulin Pumps
Technological Advances in Insulin Pump Systems
Implantable Insulin Pumps
Closed-Loop Artificial Pancreas
Bionic Pancreas
Smart Pens
Chapter 5 Global Market for Emerging Insulin Drug Delivery Devices, by Application
Overview
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Chapter 6 Global Market for for Insulin Drug Delivery Devices, by Region
Overview
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Regulatory Landscape
Overview
U.S. Regulations for Insulin Drug and Delivery Technologies
European Regulations for Insulin Drug and Delivery Technologies
Japan’s Regulations for Insulin Drug and Delivery Technologies
China’s Regulations for Insulin Drug and Delivery Technologies
Chapter 8 Sustainability in the Insulin Drug and Delivery Market: An ESG Perspective
Introduction
ESG Performance Analysis
Chapter 9 Emerging Technologies
Introduction
Patient Outcomes Beyond Glucose Control
Chapter 10 Patent Analysis
Overview
Chapter 11 M&A and Venture Funding Outlook
M&A Analysis
Chapter 12 Competitive Landscape
Overview
Chapter 13 Company Profiles
ASTRAZENECA
B. BRAUN SE
BD
CARDINAL HEALTH
DEBIOTECH SA
DIABELOOP SA
EMPERRA GMBH E-HEALTH TECHNOLOGIES
EMBECTA CORP.
F. HOFFMANN-LA ROCHE LTD.
INSULET CORP.
JOHNSON & JOHNSON SERVICES INC.
LIFESCAN IP HOLDINGS LLC.
LILLY
MEDTRONIC
NOVO NORDISK A/S
NUGEN MEDICAL DEVICES
OWEN MUMFORD LTD.
SANOFI
SOOIL DEVELOPMENTS CO. LTD.
TANDEM DIABETES CARE INC.
TERUMO CORP.
YPSOMED AG
Chapter 14 Appendix
Government Regulatory Agencies and Professional Organizations
List of References

List of Tables
Summary Table : Global Market for Emerging Insulin Drug Delivery Devices, by Type, Through 2028
Table 1 : Latest Data for Diabetes Globally, 2021 and 2045
Table 2 : Global Estimates and Projections for Diabetes, 2019–2045
Table 3 : Diabetes Cases, by Country, 2000-2045
Table 4 : Age-Adjusted Comparative Prevalence of Diabetes, by Region, 2010-2045
Table 5 : First-Time Generic Drug Approvals for Type 2 Diabetes, July 2022 to August 2022
Table 6 : Global Market for Insulin Syringes and Vials, Through 2028
Table 7 : Global Market for Insulin Syringes, by Type, Through 2028
Table 8 : Leading Manufacturers of Insulin Syringes and Insulin Syringe Products, 2022
Table 9 : Commercially Available Insulin Injector Pens
Table 10 : Leading Manufacturers of External Insulin PumpsLeading Manufacturers of External Insulin Pumps
Table 11 : Features of Current Leading Insulin Pump Systems
Table 12 : Global Market for Emerging Insulin Drug Delivery Devices, by Type, Through 2028
Table 13 : Global Market for Emerging Insulin Drug Delivery Devices, by Region, Through 2028
Table 14 : Global Market for Insulin Syringes and Vials, by Region, Through 2028
Table 15 : Global Market for Insulin Pens, by Region, Through 2028
Table 16 : Global Market for Insulin Pumps, by Region, Through 2028
Table 17 : Global Market for Smart Pens, by Region, Through 2028
Table 18 : Global Market for Insulin Vials, by Region, Through 2028
Table 19 : Global Market for Insulin Syringes, by Region, Through 2028
Table 20 : Global Market for U-100 Insulin Syringes, by Region, Through 2028
Table 21 : Global Market for U-40 Insulin Syringes, by Region, Through 2028
Table 22 : Global Market for Emerging Insulin Drug Delivery Devices, by Application, Through 2028
Table 23 : Global Market for Type 1 Diabetes, by Region, Through 2028
Table 24 : Global Market for Type 2 Diabetes, by Region, Through 2028
Table 25 : Global Market for Gestational Diabetes, by Region, Through 2028
Table 26 : Global Market for Emerging Insulin Drug Delivery Devices, by Region, Through 2028
Table 27 : North American Market for Insulin Drug Delivery Devices, by Country, Through 2028
Table 28 : North American Market for Insulin Drug Delivery Devices, by Type, Through 2028
Table 29 : North American Market for Insulin Syringes and Vials, by Segment, Through 2028
Table 30 : North American Market for Insulin Syringes, by Type, Through 2028
Table 31 : North American Market for Insulin Drug Delivery Devices, by Application, Through 2028
Table 32 : European Market for Insulin Drug Delivery Devices, by Country, Through 2028
Table 33 : European Market for Insulin Drug Delivery Devices, by Type, Through 2028
Table 34 : European Market for Insulin Syringes and Vials, by Segment, Through 2028
Table 35 : European Market for Insulin Syringes, by Type, Through 2028
Table 36 : European Market for Insulin Drug Delivery Devices, by Application, Through 2028
Table 37 : Asia-Pacific Market for Insulin Drug Delivery Devices, by Country, Through 2028
Table 38 : Asia-Pacific Market for Insulin Drug Delivery Devices, by Type, Through 2028
Table 39 : Asia-Pacific Market for Insulin Syringes and Vials, by Segment, Through 2028
Table 40 : Asia-Pacific Market for Insulin Syringes, by Type, Through 2028
Table 41 : Asia-Pacific Market for Insulin Drug Delivery Devices, by Application, Through 2028
Table 42 : RoW Market for Insulin Drug Delivery Devices, by Sub-region, Through 2028
Table 43 : RoW Market for Insulin Drug Delivery Devices, by Type, Through 2028
Table 44 : RoW Market for Insulin Syringes and Vials, by Segment, Through 2028
Table 45 : RoW Market for Insulin Syringes, by Type, Through 2028
Table 46 : RoW Market for Insulin Drug Delivery Devices, by Application, Through 2028
Table 47 : ESG Performance Analysis of the Market for Insulin Drug and Delivery Technologies
Table 48 : Social Performance of the Market for Insulin Drug and Delivery Technologies
Table 49 : Governance Performance of the Market for Insulin Drug and Delivery Technologies
Table 50 : Clinical Trials Involving Insulin Drug and Delivery Technologies
Table 51 : Clinical Trials Involving Artificial Pancreas, as of December 2023
Table 52 : Approved Active Patents for Insulin Drug Delivery Devices, 2021-2023
Table 53 : M&A in the Global Market for Insulin Drug Delivery Devices, 2021 to June 2023
Table 54 : Recent Venture Funding for Insulin Drug Delivery Devices and Related Offerings
Table 55 : Number of Deals for Insulin Drug and Delivery Technologies, by Status, January 2018 to September 2023
Table 56 : Leading Manufacturers and Suppliers of Insulin Syringes and Vials
Table 57 : Ranking of Insulin Syringe Manufacturers, by Market Share, 2022
Table 58 : Ranking of Insulin Vial Manufacturers, by Market Share, 2022
Table 59 : Global Market Ranking for Insulin Drug Delivery Devices, 2022
Table 60 : AstraZeneca: Company Snapshot
Table 61 : AstraZeneca: Financial Performance, FY 2022-2023
Table 62 : AstraZeneca: Product Portfolio
Table 63 : AstraZeneca: Key/Recent Developments, 2021-2023
Table 64 : B. Braun SE: Company Snapshot
Table 65 : B. Braun SE: Financials, FY 2021–2022
Table 66 : B. Braun SE: Product Portfolio
Table 67 : B. Braun SE: News/Key Developments, 2023
Table 68 : BD: Company Snapshot
Table 69 : BD: Financial Performance, FY 2022-2023
Table 70 : BD: Product Portfolio
Table 71 : BD: News/Key Developments, 2021-2023
Table 72 : Cardinal Health: Company Snapshot
Table 73 : Cardinal Health: Financial Performance, FY 2022-2023
Table 74 : Cardinal Health: Product Portfolio
Table 75 : Cardinal Health: News/Key Developments, 2021-2023
Table 76 : Debiotech SA: Company Snapshot
Table 77 : Debiotech SA: Product Portfolio
Table 78 : Debiotech SA: News/Key Developments, 2022-2023
Table 79 : Diabeloop SA: Company Snapshot
Table 80 : Diabeloop SA: Product Portfolio
Table 81 : Diabeloop SA: News/Key Developments, 2021-2023
Table 82 : Emperra GmbH E-Health Technologies: Company Snapshot
Table 83 : Emperra GmbH E-Health Technologies: Product Portfolio
Table 84 : Emperra GmbH E-Health Technologies: News/Key Developments, 2022
Table 85 : Embecta Corp.: Company Snapshot
Table 86 : Embecta Corp.: Financial Performance, FY 2022-2023
Table 87 : Embecta Corp.: Product Portfolio
Table 88 : Embecta Corp.: News/Key Developments, 2021-2023
Table 89 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 90 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022-2023
Table 91 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 92 : Insulet Corp.: Company Snapshot
Table 93 : Insulet Corp.: Financial Performance, FY 2022-2023
Table 94 : Insulet Corp.: Product Portfolio
Table 95 : Insulet Corp.: News/Key Developments, 2023
Table 96 : Johnson & Johnson Services Inc.: Company Snapshot
Table 97 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022-2023
Table 98 : Johnson & Johnson Services Inc.: Product Portfolio
Table 99 : Johnson & Johnson Services Inc.: News/Key Developments, 2021-2023
Table 100 : LifeScan IP Holdings LLC.: Company Snapshot
Table 101 : LifeScan IP Holdings LLC.: Product Portfolio
Table 102 : LifeScan IP Holdings LLC.: News/Key Developments, 2021
Table 103 : Lilly: Company Snapshot
Table 104 : Lilly: Financial Performance, FY 2022-2023
Table 105 : Lilly: Product Portfolio
Table 106 : Lilly: Recent Developments, 2021-2022
Table 107 : Medtronic: Company Snapshot
Table 108 : Medtronic: Financial Performance, FY 2022-2023
Table 109 : Medtronic: Product Portfolio
Table 110 : Medtronic: News/Key Developments, 2021-2023
Table 111 : Novo Nordisk A/S: Company Snapshot
Table 112 : Novo Nordisk A/S: Financial Performance, FY 2022-2023
Table 113 : Novo Nordisk A/S: Product Portfolio
Table 114 : Novo Nordisk A/S: Recent Developments, 2021-2023
Table 115 : NuGen Medical Devices: Company Snapshot
Table 116 : NuGen Medical Devices: Financial Performance, FY 2021–2022
Table 117 : NuGen Medical Devices: Product Portfolio
Table 118 : NuGen Medical Devices: News/Key Developments, 2022
Table 119 : Owen Mumford Ltd.: Company Snapshot
Table 120 : Owen Mumford Ltd.: Product Portfolio
Table 121 : Sanofi: Company Snapshot
Table 122 : Sanofi: Financial Performance, FY 2022-2023
Table 123 : Sanofi: Product Portfolio
Table 124 : Sanofi: Recent Developments, 2022-2023
Table 125 : Sooil Developments Co. Ltd.: Company Snapshot
Table 126 : Sooil Developments Co. Ltd.: Product Portfolio
Table 127 : Tandem Diabetes Care Inc.: Company Snapshot
Table 128 : Tandem Diabetes Care Inc.: Financial Performance, FY 2022-2023
Table 129 : Tandem Diabetes Care Inc.: Product Portfolio
Table 130 : Tandem Diabetes Care Inc.: News/Key Developments, 2023-2024
Table 131 : Terumo Corp.: Company Snapshot
Table 132 : Terumo Corp.: Financial Performance, FY 2021-2022
Table 133 : Terumo Corp.: Product Portfolio
Table 134 : Terumo Corp.: News/Key Developments, 2022
Table 135 : Ypsomed AG: Company Snapshot
Table 136 : Ypsomed AG: Financial Performance, FY 2021-2022
Table 137 : Ypsomed AG: Product Portfolio
Table 138 : Ypsomed AG: News/Key Developments, 2022-2023
Table 139 : Government Regulatory Agencies and Professional Organizations

List of Figures
Summary Figure : Global Market for Emerging Insulin Drug Delivery Devices, by Type, 2020-2028
Figure 1 : Market Dynamics for Emerging Insulin Drug and Delivery Technologies
Figure 2 : Snapshot of the Worldwide Incidence of Diabetes, 2019–2045
Figure 3 : AstraZeneca: Revenue Share, by Segment, 2023
Figure 4 : AstraZeneca: Revenue Share, by Region/Country, 2023
Figure 5 : B. Braun SE: Revenue Share, by Business Unit, FY 2022
Figure 6 : B. Braun SE: Revenue Share, by Region/Country, FY 2022
Figure 7 : BD: Revenue Share, by Business Unit, FY 2023
Figure 8 : BD: Revenue Share, by Region/Country, FY 2023
Figure 9 : Cardinal Health: Revenue Share, by Business Unit, FY 2023
Figure 10 : Cardinal Health: Revenue Share, by Region/Country, FY 2023
Figure 11 : Embecta Corp.: Revenue Share, by Region/Country, FY 2023
Figure 12 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 13 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Region/Country, FY 2023
Figure 14 : Insulet Corp.: Revenue Share, by Business Unit, FY 2023
Figure 15 : Insulet Corp.: Revenue Share, by Region/Country, FY 2023
Figure 16 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
Figure 17 : Johnson & Johnson Services Inc.: Revenue Share, by Region/Country, FY 2023
Figure 18 : Lilly: Revenue Share, by Product Type, FY 2023
Figure 19 : Lilly: Revenue Share, by Region/Country, FY 2023
Figure 20 : Medtronic: Revenue Share, by Business Unit, FY 2023
Figure 21 : Medtronic: Revenue Share, by Region/Country, FY 2023
Figure 22 : Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2023
Figure 23 : Novo Nordisk A/S: Revenue Share, by Region/Country, FY 2023
Figure 24 : NuGen Medical Devices: Revenue Share, by Region, FY 2022
Figure 25 : Sanofi: Revenue Share, by Business Segment, FY 2023
Figure 26 : Sanofi: Revenue Share, by Region, 2023
Figure 27 : Tandem Diabetes Care Inc.: Revenue Share, by Region/Country, FY 2023
Figure 28 : Terumo Corp.: Revenue Share, by Business Unit, FY 2022
Figure 29 : Terumo Corp.: Revenue Share, by Region/Country, FY 2022
Figure 30 : Ypsomed AG: Revenue Share, by Business Unit, FY 2022
Figure 31 : Ypsomed AG: Revenue Share, by Region/Country, FY 2022